316 wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050– 4058 Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocam- pal neurons. J Neurosci 20:3214–3220 Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anaﬁ D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M (1999) Both familial Parkinson’s disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 274:9843–9846 Nixon RA, Cataldo AM (2006) Lysosomal system pathways: genes to neurodegeneration in Alzheimer’s disease. J Alzheimers Dis 9:277–289 Perry E (1995) Cholinergic signaling in Alzheimer disease: thera- peutic strategies. Alzheimer Dis Assoc Disord 9(Suppl 2):1–2 Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2:1457–1459 Pettegrew J (1989) Molecular insights into Alzheimer’s disease. In: Boller F, Katzman R, Rascol A, Signoret J-L, Christen Y (eds) Biological markers of Alzheimer’s disease. Springer-Verlag, New York, pp 83–104 Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC (2005) Abeta deposition is associ- ated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 26:1183–1192 Price DL, Wong PC, Markowska AL, Lee MK, Thinakaren G, Cleveland DW, Sisodia SS, Borchelt DR (2000) The value of transgenic models for the study of neurodegenerative diseases. Ann N Y Acad Sci 920:179–191 Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R (2005) Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 102:10427–10432 Richﬁeld EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ (2002) Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol 175:35– 48 Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, Bieganski RM, Lindquist SL, Lansbury PT (2004) Interac- tions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson’s disease. J Mol Neurosci 23:23–34 Rockenstein E, McConlogue L, Tan H, Power M, Masliah E, Mucke L (1995) Levels and alternative splicing of amyloid b protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer’s disease. J Biol Chem 270:28257– 28267 Rockenstein E, Mallory M, Mante M, Sisk A, Masliah E (2001) Early formation of mature amyloid-b proteins deposits in a mutant APP transgenic model depends on levels of Ab1-42. J Neurosci Res 66:573–582 Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet- derived growth factor and Thy-1 promoters. J Neurosci Res 68:568–578 Rosenberg RN (2005) New presenilin 1 mutation with Alzheimer disease and Lewy bodies. Arch Neurol 62:1808 Scheff SW, DeKosky ST, Price DA (1990) Quantitative assessment of cortical synaptic density in Alzheimer’s disease. Neurobiol Aging 11:29–37 123 Neurotox Res (2009) 16:306–317 Selkoe D (1990) Amyloid b-protein deposition as a seminal pathogenic event in AD: an hypothesis. Neurobiol Aging 11:299 Selkoe DJ (1994a) Alzheimer’s disease: a central role for amyloid. J Neuropathol Exp Neurol 53:438–447 Selkoe DJ (1994b) Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer’s disease. Annu Rev Cell Biol 10:373–403 Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature 399:A23–A31 Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, John V et al (1999) Puriﬁcation and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402:537–540 Sinha S, Anderson J, John V, McConlogue L, Basi G, Thorsett E, Schenk D (2000) Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann N Y Acad Sci 920:206–208 Sisodia SS, Price DL (1995) Role of the beta-amyloid protein in Alzheimer’s disease. FASEB J 9:366–370 Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R, Lendon CL, Goate AM, McKeel DW Jr, Morris JC (2005) Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol 62:1821– 1830 Soto C, Branes MC, Alvarez J, Inestrosa NC (1994) Structural determinants of the Alzheimer’s amyloid beta-peptide. J Neu- rochem 63:1191–1198 Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett 251:205–208 Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT (2005) Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 25:7278–7287 Sturchler-Pierrat C, Abramowski D, Duke M, Wiederholt K, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti P, Waridel C, Calhoun M, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94:13287–13292 Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580 Trojanowski JQ, Lee VM (2000) ‘‘Fatal attractions’’ of proteins. A comprehensive hypothetical mechanism underlying Alzheimer’s disease and other neurodegenerative disorders. Ann N Y Acad Sci 924:62–67 Trojanowski JQ, Schmidt ML, Shin RW, Bramblett GT, Rao D, Lee VM (1993) Altered tau and neuroﬁlament proteins in neuro- degenerative diseases: diagnostic implications for Alzheimer’s disease and Lewy body dementias. Brain Pathol 3:45–54 Trojanowski JQ, Goedert M, Iwatsubo T, Lee VM (1998) Fatal attractions: abnormal protein aggregation and neuron death in Parkinson’s disease and Lewy body dementia. Cell Death Differ 5:832–837 Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, Keller SH, Platoshyn O, Yuan JX, Masliah E (2007) Dynamics of alpha-synuclein aggregation and inhibition of pore- like oligomer development by beta-synuclein. FEBS J 274: 1862–1877